The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema
The Influence of Intravitreal Ranibizumab on Inflammation-associated Cytokine Concentrations in Eyes With Diabetic Macular Edema
复制标题
DOI：
10.1167/iovs.17-23325
复制
发表时间：
2018-11-01
影响因子：
4.4
通讯作者：
Wickremasinghe, Sanjeewa S.
中科院分区：
文献类型：
--
作者：
Lim, Shueh Wen;Bandala-Sanchez, Esther;Wickremasinghe, Sanjeewa S.
目的。目的探讨玻璃体内注射雷尼比珠单抗对糖尿病黄斑水肿(DME)患者房水中血管生成或炎性细胞因子浓度的影响。所有患者的中心黄斑厚度(CMT；)均为300微米，最佳矫正视力(BCVA)介于28至70个对数MAR字母(相当于Snellen的20/320-20/40)。在基线时，所有眼睛在雷尼比珠单抗治疗前收集了0.1mL房水。在第4周，第二次注射雷尼比珠单抗，在第8周，在第三次雷尼比单抗注射之前重复水样。从第12周开始，每隔4周对所有眼睛进行跟踪观察，并通过BCVA和CMT测量确定是否需要雷尼比珠单抗治疗。结果：连续两次注射雷尼比珠单抗后，血管内皮生长因子(P<；0.00001)、IL-1β(P=0.00006)、IL-7(P=0.00002)、IL-8(P=0.00023)、IL-10(P<；0.00001)、IL-12(P<；0.00001)、IL-17(P=0.00024)、单核细胞趋化蛋白-1(P=0.00023)和肿瘤坏死因子-α(P=0.00001)。可溶性血管内皮生长因子受体-2表达上调(P=0.00004)。P<；0.0015在本研究中被认为具有重要意义。结论：雷尼比珠单抗治疗除了降低二甲基苯丙胺患者房水中血管内皮生长因子的浓度外，还影响各种炎症细胞因子的浓度。这可能有助于其对DME患者的治疗效果。
PURPOSE. To evaluate the effect of intravitreal ranibizumab injections on aqueous concentrations of angiogenic or inflammatory cytokines in patients with diabetic macular edema (DME).METHODS. Thirty eyes of 25 patients with center-involved DME were recruited to the study. All had a central macular thickness (CMT) of >300 mu m and best-corrected visual acuity (BCVA) between 28 and 70 logMAR letters (Snellen equivalent 20/320-20/40). At baseline, all eyes had 0.1 mL of aqueous collected before ranibizumab treatment. At week 4, a second ranibizumab injection was administered and at week 8, aqueous sampling was repeated before a third ranibizumab injection. From week 12, all eyes were followed at 4-weekly intervals and the need for ranibizumab treatment was determined by BCVA and CMT measurements. Levels of 32 cytokines were assessed at baseline and at week 8 using a multiplex array assay.RESULTS. Following two consecutive ranibizumab injections, there was a statistically significant reduction in VEGF (P < 0.00001), as well as IL-1 beta (P = 0.00006), IL-7 (P = 0.00002), IL-8 (P = 0.00023), IL-10 (P < 0.00001), IL-12 (P < 0.00001), IL-17 (P = 0.00024), MCP-1 (P = 0.00023), and TNF-alpha (P < 0.00001). There was also an upregulation of soluble VEGF receptor-2 (P = 0.00004). A P < 0.0015 was considered significant in this study.CONCLUSIONS. Ranibizumab treatment influences various inflammatory cytokine concentrations in addition to reducing aqueous VEGF concentrations in patients with DME. This may contribute to its therapeutic effect in patients with DME.